BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26004183)

  • 1. Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.
    Sujobert P; Poulain L; Paubelle E; Zylbersztejn F; Grenier A; Lambert M; Townsend EC; Brusq JM; Nicodeme E; Decrooqc J; Nepstad I; Green AS; Mondesir J; Hospital MA; Jacque N; Christodoulou A; Desouza TA; Hermine O; Foretz M; Viollet B; Lacombe C; Mayeux P; Weinstock DM; Moura IC; Bouscary D; Tamburini J
    Cell Rep; 2015 Jun; 11(9):1446-57. PubMed ID: 26004183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Co-activation of AMPK and mTORC1: a therapeutic application of synthetic lethality in acute myeloid leukemia].
    Tamburini J; Poulain L; Bouscary D; Sujobert P
    Med Sci (Paris); 2015 Oct; 31(10):836-9. PubMed ID: 26481022
    [No Abstract]   [Full Text] [Related]  

  • 3. GSK621 Targets Glioma Cells via Activating AMP-Activated Protein Kinase Signalings.
    Jiang H; Liu W; Zhan SK; Pan YX; Bian LG; Sun B; Sun QF; Pan SJ
    PLoS One; 2016; 11(8):e0161017. PubMed ID: 27532105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-activation of AMPK and mTORC1 as a new therapeutic option for acute myeloid leukemia.
    Sujobert P; Tamburini J
    Mol Cell Oncol; 2016 Jul; 3(4):e1071303. PubMed ID: 27652311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMPK activation by GSK621 inhibits human melanoma cells in vitro and in vivo.
    Chen L; Chen Q; Deng G; Kuang S; Lian J; Wang M; Zhu H
    Biochem Biophys Res Commun; 2016 Nov; 480(4):515-521. PubMed ID: 27751856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer.
    Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH
    Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia.
    Grenier A; Poulain L; Mondesir J; Jacquel A; Bosc C; Stuani L; Mouche S; Larrue C; Sahal A; Birsen R; Ghesquier V; Decroocq J; Mazed F; Lambert M; Andrianteranagna M; Viollet B; Auberger P; Lane AA; Sujobert P; Bouscary D; Sarry JE; Tamburini J
    Cell Rep; 2022 Jan; 38(1):110197. PubMed ID: 34986346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Energy depletion of bovine mammary epithelial cells activates AMPK and suppresses protein synthesis through inhibition of mTORC1 signaling.
    Burgos SA; Kim JJ; Dai M; Cant JP
    Horm Metab Res; 2013 Mar; 45(3):183-9. PubMed ID: 22972179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo.
    Zhang Y; Xu S; Lin J; Yao G; Han Z; Liang B; Zou Z; Chen Z; Song Q; Dai Y; Gao T; Liu A; Bai X
    Breast Cancer Res Treat; 2012 Nov; 136(2):379-88. PubMed ID: 23053656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
    Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia.
    Ghosh J; Kapur R
    Exp Hematol; 2017 Jun; 50():13-21. PubMed ID: 28342808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
    Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
    Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative regulation of the LKB1/AMPK pathway by ERK in human acute myeloid leukemia cells.
    Kawashima I; Mitsumori T; Nozaki Y; Yamamoto T; Shobu-Sueki Y; Nakajima K; Kirito K
    Exp Hematol; 2015 Jul; 43(7):524-33.e1. PubMed ID: 25846811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Gery S; Koeffler HP; Yokoyama A
    Int J Cancer; 2009 Oct; 125(7):1710-20. PubMed ID: 19507250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted activation of AMPK by GSK621 ameliorates H2O2-induced damages in osteoblasts.
    Liu W; Mao L; Ji F; Chen F; Hao Y; Liu G
    Oncotarget; 2017 Feb; 8(6):10543-10552. PubMed ID: 28060740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Roles of mTORC1 in acute myeloid leukemia].
    Hoshii T; Hirao A
    Rinsho Ketsueki; 2015 Apr; 56(4):359-65. PubMed ID: 25971265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSK621 attenuates oxygen glucose deprivation/re-oxygenation-induced myocardial cell injury via AMPK-dependent signaling.
    Ting-Ting L; Yuan G; Jun L; Dan X; Hong-Bo T
    Biochem Biophys Res Commun; 2019 Jun; 514(3):826-834. PubMed ID: 31079918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
    Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.
    Park S; Chapuis N; Bardet V; Tamburini J; Gallay N; Willems L; Knight ZA; Shokat KM; Azar N; Viguié F; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
    Leukemia; 2008 Sep; 22(9):1698-706. PubMed ID: 18548104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
    Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
    J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.